Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Raw Materials (2019 - 2025)

Ptc Therapeutics has reported Raw Materials over the past 7 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Raw Materials at $2.3 million for Q4 2025, down 9.73% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 9.73% YoY), and the annual figure for FY2025 was $2.3 million, down 9.73%.
  • Raw Materials for Q4 2025 was $2.3 million at Ptc Therapeutics, up from $2.2 million in the prior quarter.
  • Over the last five years, Raw Materials for PTCT hit a ceiling of $2.7 million in Q3 2024 and a floor of $678000.0 in Q1 2021.
  • Median Raw Materials over the past 5 years was $1.3 million (2022), compared with a mean of $1.5 million.
  • Biggest five-year swings in Raw Materials: dropped 26.92% in 2023 and later surged 201.87% in 2024.
  • Ptc Therapeutics' Raw Materials stood at $1.4 million in 2021, then fell by 23.98% to $1.1 million in 2022, then fell by 11.69% to $952000.0 in 2023, then skyrocketed by 166.6% to $2.5 million in 2024, then fell by 9.73% to $2.3 million in 2025.
  • The last three reported values for Raw Materials were $2.3 million (Q4 2025), $2.2 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.